Search Results - "Azetidines"

Phenylvinylsulfonate-Anchored Azetidin-2-ones as Potent Antibacterial Agents: ROS-Mediated Mechanism, Selective Cytotoxicity, and In Silico Target-Interaction Studies.

Authors: Thakur S Sharma R Wangoo N et al.

Source: Archiv der Pharmazie [Arch Pharm (Weinheim)] 2025 Dec; Vol. 358 (12), pp. e70163.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-VCH Verlag GmbH & Co. KGaA Country of Publication: Germany NLM ID: 0330167 Publication Model: Print Cited Medium: Internet ISSN: 1521-4184 (Electronic) Linking ISSN: 03656233 NLM ISO Abbreviation: Arch Pharm (Weinheim) Subsets: MEDLINE

MeSH Terms: Anti-Bacterial Agents*/pharmacology , Anti-Bacterial Agents*/chemical synthesis , Anti-Bacterial Agents*/chemistry , Reactive Oxygen Species*/metabolism , Azetidines*/pharmacology , Azetidines*/chemistry , Azetidines*/chemical synthesis , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemical synthesis , Antineoplastic Agents*/chemistry , Vinyl Compounds*/pharmacology , Vinyl Compounds*/chemistry , Vinyl Compounds*/chemical synthesis , Sulfonic Acids*/chemistry , Sulfonic Acids*/pharmacology , Sulfonic Acids*/chemical synthesis, Microbial Sensitivity Tests ; Molecular Docking Simulation ; Humans ; Structure-Activity Relationship ; Molecular Structure ; Animals ; Mice ; Dose-Response Relationship, Drug ; Methicillin-Resistant Staphylococcus aureus/drug effects ; Cell Survival/drug effects

Siponimod inhibits disease-associated microglia-T cell interactions in chronic experimental autoimmune encephalomyelitis.

Authors: Husseini L Geladaris A Steinleitner MCJ et al.

Source: Acta neuropathologica communications [Acta Neuropathol Commun] 2025 Dec 01; Vol. 13 (1), pp. 247. Date of Electronic Publication: 2025 Dec 01.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101610673 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-5960 (Electronic) Linking ISSN: 20515960 NLM ISO Abbreviation: Acta Neuropathol Commun Subsets: MEDLINE

MeSH Terms: Encephalomyelitis, Autoimmune, Experimental*/drug therapy , Encephalomyelitis, Autoimmune, Experimental*/pathology , Encephalomyelitis, Autoimmune, Experimental*/immunology , Microglia*/drug effects , Microglia*/pathology , Azetidines*/pharmacology , Azetidines*/therapeutic use , Benzyl Compounds*/pharmacology , Benzyl Compounds*/therapeutic use , T-Lymphocytes*/drug effects , Sphingosine 1 Phosphate Receptor Modulators*/pharmacology , Sphingosine 1 Phosphate Receptor Modulators*/therapeutic use , Cell Communication*/drug effects, Animals ; Mice, Inbred C57BL ; Female ; Mice ; Humans ; Coculture Techniques ; Peptide Fragments/toxicity ; Cells, Cultured ; Disease Models, Animal

Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial.

Authors: Wollenberg A Costanzo A Vestergaard C et al.

Source: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2585244. Date of Electronic Publication: 2025 Nov 27.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

MeSH Terms: Dermatitis, Atopic*/drug therapy , Dermatitis, Atopic*/diagnosis , Dermatitis, Atopic*/complications , Azetidines*/administration & dosage , Azetidines*/therapeutic use , Azetidines*/adverse effects , Sulfonamides*/administration & dosage , Sulfonamides*/therapeutic use , Quality of Life* , Pruritus*/drug therapy , Pruritus*/etiology , Dermatologic Agents*/administration & dosage, Humans ; Purines ; Adult ; Female ; Male ; Severity of Illness Index ; Treatment Outcome ; Middle Aged ; Pyrazoles ; Double-Blind Method ; Young Adult

Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study.

Authors: Muñoz-Barba D García-Moronta C Haselgruber-de Francisco S et al.

Source: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2583877. Date of Electronic Publication: 2025 Nov 24.

Publication Type: Journal Article; Observational Study

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

MeSH Terms: Alopecia Areata*/drug therapy , Alopecia Areata*/diagnosis , Azetidines*/adverse effects , Azetidines*/therapeutic use , Azetidines*/administration & dosage , Sulfonamides*/adverse effects , Sulfonamides*/therapeutic use , Sulfonamides*/administration & dosage , Pyrazoles*/adverse effects , Pyrazoles*/therapeutic use, Humans ; Purines/adverse effects ; Female ; Male ; Prospective Studies ; Adult ; Middle Aged ; Treatment Outcome ; Severity of Illness Index ; Young Adult ; Follow-Up Studies

Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study.

Authors: Vignoli CA Gargiulo L Ibba L et al.

Source: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2444494. Date of Electronic Publication: 2025 Jan 06.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

MeSH Terms: Azetidines*/therapeutic use , Azetidines*/administration & dosage , Alopecia Areata*/drug therapy , Sulfonamides*/administration & dosage , Sulfonamides*/therapeutic use , Pyrazoles*/administration & dosage , Pyrazoles*/therapeutic use , Purines*/therapeutic use , Purines*/administration & dosage , Severity of Illness Index*, Humans ; Retrospective Studies ; Male ; Female ; Adult ; Middle Aged ; Treatment Outcome ; Janus Kinase Inhibitors/therapeutic use ; Janus Kinase Inhibitors/administration & dosage ; Janus Kinase Inhibitors/adverse effects ; Young Adult ; Italy

Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors.

Authors: Gori N Di Nardo L Ippoliti E et al.

Source: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2578249. Date of Electronic Publication: 2025 Nov 03.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

MeSH Terms: Dermatitis, Atopic*/drug therapy , Dermatitis, Atopic*/diagnosis , Purines*/adverse effects , Purines*/administration & dosage , Azetidines*/adverse effects , Azetidines*/administration & dosage , Azetidines*/therapeutic use , Sulfonamides*/adverse effects , Sulfonamides*/administration & dosage , Pyrazoles*/adverse effects , Pyrazoles*/administration & dosage , Dermatologic Agents*/adverse effects , Dermatologic Agents*/administration & dosage, Humans ; Male ; Adult ; Female ; Middle Aged ; Treatment Outcome ; Severity of Illness Index ; Retrospective Studies ; Patient Reported Outcome Measures ; Prospective Studies ; Quality of Life ; Italy

Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study.

Authors: Niki M Kamata M Tada Y et al.

Source: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2555684. Date of Electronic Publication: 2025 Sep 07.

Publication Type: Journal Article; Review

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

MeSH Terms: Alopecia Areata*/drug therapy , Alopecia Areata*/diagnosis , Azetidines*/adverse effects , Azetidines*/therapeutic use , Azetidines*/administration & dosage , Sulfonamides*/adverse effects , Sulfonamides*/therapeutic use , Sulfonamides*/administration & dosage , Pyrazoles*/adverse effects , Pyrazoles*/therapeutic use , Pyrazoles*/administration & dosage, Humans ; Purines/adverse effects ; Male ; Female ; Retrospective Studies ; Adult ; Treatment Outcome ; Middle Aged ; Time Factors ; Young Adult ; Japan ; Adolescent ; East Asian People ; Alopecia

SCR Disease Name: Alopecia universalis

An ICH Q14-Guided AQbD Framework for the Development of an HPLC Method: Analysis of Siponimod Fumarate and Its Impurities.

Authors: Altwala A Algohary AM Alhalafi MH et al.

Source: Electrophoresis [Electrophoresis] 2025 Dec; Vol. 46 (23), pp. 1661-1672. Date of Electronic Publication: 2025 Sep 23.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 8204476 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-2683 (Electronic) Linking ISSN: 01730835 NLM ISO Abbreviation: Electrophoresis Subsets: MEDLINE

MeSH Terms: Azetidines*/analysis , Azetidines*/chemistry, Chromatography, High Pressure Liquid/methods ; Drug Contamination ; Reproducibility of Results ; Linear Models ; Limit of Detection ; Tablets/chemistry

A real-world retrospective study to assess the effectiveness and safety profile of siponimod in Chinese patients with relapsing forms of multiple sclerosis.

Authors: Zhang Y Liu H Li Z et al.

Source: BMC neurology [BMC Neurol] 2025 Nov 28; Vol. 25 (1), pp. 491. Date of Electronic Publication: 2025 Nov 28.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100968555 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2377 (Electronic) Linking ISSN: 14712377 NLM ISO Abbreviation: BMC Neurol Subsets: MEDLINE

MeSH Terms: Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Multiple Sclerosis, Relapsing-Remitting*/diagnostic imaging , Azetidines*/adverse effects , Azetidines*/therapeutic use , Benzyl Compounds*/adverse effects , Benzyl Compounds*/therapeutic use , Sphingosine 1 Phosphate Receptor Modulators*/therapeutic use , Sphingosine 1 Phosphate Receptor Modulators*/adverse effects, Humans ; Female ; Male ; Retrospective Studies ; Adult ; China ; Middle Aged ; Treatment Outcome ; Young Adult ; Magnetic Resonance Imaging ; East Asian People

Dual Mechanisms of Cognitive Function and Pathological Improvements by the Selective S1PR1/5 Modulator Siponimod in 3xTg-AD Mice.

Authors: Tang C Ding Y Yang S et al.

Source: Molecular neurobiology [Mol Neurobiol] 2025 Nov 22; Vol. 63 (1), pp. 133. Date of Electronic Publication: 2025 Nov 22.

Publication Type: Journal Article

Journal Info: Publisher: Humana Press Country of Publication: United States NLM ID: 8900963 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-1182 (Electronic) Linking ISSN: 08937648 NLM ISO Abbreviation: Mol Neurobiol Subsets: MEDLINE

MeSH Terms: Alzheimer Disease*/drug therapy , Alzheimer Disease*/pathology , Alzheimer Disease*/metabolism , Alzheimer Disease*/physiopathology , Cognition*/drug effects , Benzyl Compounds*/pharmacology , Benzyl Compounds*/therapeutic use , Azetidines*/pharmacology , Azetidines*/therapeutic use , Sphingosine-1-Phosphate Receptors*/metabolism , Sphingosine 1 Phosphate Receptor Modulators*/pharmacology , Sphingosine 1 Phosphate Receptor Modulators*/therapeutic use, Animals ; Microglia/drug effects ; Microglia/metabolism ; Microglia/pathology ; Mice ; Mice, Transgenic ; Disease Models, Animal ; Molecular Docking Simulation ; Signal Transduction/drug effects ; Male ; Cell Line ; Myelin Sheath/metabolism ; Myelin Sheath/drug effects

Design, In Silico, and Experimental Evaluation of Novel Naproxen-Azetidinone Hybrids as Selective COX-2 Inhibitors.

Authors: Khan AK Mahmood NR Sahib MA

Source: Molecules (Basel, Switzerland) [Molecules] 2025 Nov 11; Vol. 30 (22). Date of Electronic Publication: 2025 Nov 11.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE

MeSH Terms: Naproxen*/chemistry , Naproxen*/pharmacology , Cyclooxygenase 2 Inhibitors*/chemistry , Cyclooxygenase 2 Inhibitors*/pharmacology , Cyclooxygenase 2 Inhibitors*/chemical synthesis , Cyclooxygenase 2*/chemistry , Cyclooxygenase 2*/metabolism , Azetidines*/chemistry , Azetidines*/pharmacology , Drug Design*, Animals ; Molecular Docking Simulation ; Rats ; Anti-Inflammatory Agents, Non-Steroidal/chemistry ; Anti-Inflammatory Agents, Non-Steroidal/pharmacology ; Edema/drug therapy ; Male ; Molecular Structure ; Humans ; Structure-Activity Relationship

Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.

Authors: Hong SJ Kim JH Cha KS et al.

Source: Clinical therapeutics [Clin Ther] 2025 Nov; Vol. 47 (11), pp. 1028-1036. Date of Electronic Publication: 2025 Sep 14.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III

Journal Info: Publisher: Excerpta Medica Country of Publication: United States NLM ID: 7706726 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-114X (Electronic) Linking ISSN: 01492918 NLM ISO Abbreviation: Clin Ther Subsets: MEDLINE

MeSH Terms: Hypertension*/drug therapy , Hypertension*/complications , Pyrimidines*/adverse effects , Pyrimidines*/therapeutic use , Pyrimidines*/administration & dosage , Atorvastatin*/adverse effects , Atorvastatin*/therapeutic use , Atorvastatin*/administration & dosage , Biphenyl Compounds*/adverse effects , Biphenyl Compounds*/therapeutic use , Biphenyl Compounds*/administration & dosage , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/adverse effects , Anticholesteremic Agents*/administration & dosage , Tetrazoles*/adverse effects , Tetrazoles*/therapeutic use , Tetrazoles*/administration & dosage , Hypercholesterolemia*/drug therapy , Hypercholesterolemia*/complications , Dyslipidemias*/drug therapy , Dyslipidemias*/complications , Azetidines*/adverse effects , Azetidines*/therapeutic use , Azetidines*/administration & dosage , Antihypertensive Agents*/therapeutic use , Antihypertensive Agents*/adverse effects , Antihypertensive Agents*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Drug Therapy, Combination ; Double-Blind Method ; Ezetimibe/adverse effects ; Ezetimibe/therapeutic use ; Aged ; Republic of Korea ; Blood Pressure/drug effects ; Treatment Outcome ; Cholesterol, LDL/blood

Discovery and Mechanism of a Diiron Enzyme in Ethylidene Azetidine Formation.

Authors: Shen Y Zheng YC Palacios PM et al.

Source: Journal of the American Chemical Society [J Am Chem Soc] 2025 Oct 22; Vol. 147 (42), pp. 38627-38635. Date of Electronic Publication: 2025 Oct 13.

Publication Type: Journal Article

Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 7503056 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-5126 (Electronic) Linking ISSN: 00027863 NLM ISO Abbreviation: J Am Chem Soc Subsets: MEDLINE

MeSH Terms: Azetidines*/chemistry , Azetidines*/metabolism , Iron*/chemistry , Iron*/metabolism , Oxidoreductases*/metabolism , Oxidoreductases*/chemistry, Models, Molecular ; Crystallography, X-Ray ; Oxygen/metabolism ; Oxygen/chemistry

Nanoparticles coated with immune cell hybrid membranes for targeted delivery of janus kinase inhibitors and synergistic treatment of autoimmune myocarditis.

Authors: Zhang Z Xiong Y Liu S et al.

Source: Acta biomaterialia [Acta Biomater] 2025 Oct 01; Vol. 205, pp. 584-600. Date of Electronic Publication: 2025 Sep 11.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101233144 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-7568 (Electronic) Linking ISSN: 17427061 NLM ISO Abbreviation: Acta Biomater Subsets: MEDLINE

MeSH Terms: Myocarditis*/drug therapy , Myocarditis*/pathology , Myocarditis*/immunology , Autoimmune Diseases*/drug therapy , Autoimmune Diseases*/pathology , Autoimmune Diseases*/immunology , Nanoparticles*/chemistry , Nanoparticles*/therapeutic use , Sulfonamides*/pharmacology , Sulfonamides*/chemistry , Sulfonamides*/therapeutic use , Sulfonamides*/pharmacokinetics , Janus Kinase Inhibitors*/pharmacology , Janus Kinase Inhibitors*/therapeutic use , Janus Kinase Inhibitors*/chemistry , Janus Kinase Inhibitors*/pharmacokinetics , Pyrazoles*/pharmacology , Pyrazoles*/chemistry , Pyrazoles*/therapeutic use , Azetidines*/pharmacology , Azetidines*/chemistry , Azetidines*/therapeutic use , Azetidines*/pharmacokinetics , Membranes, Artificial* , Drug Delivery Systems*, Animals ; Mice ; Purines/pharmacology ; RAW 264.7 Cells ; Male ; Indoles/chemistry ; Indoles/pharmacology ; Macrophages ; Polymers/chemistry ; Mice, Inbred BALB C

Significance of miRNA Profile of Regulatory T Cells (Tregs) After Baricitinib Treatment in Rheumatoid Arthritis Patients.

Authors: Massalska M Felis-Giemza A Gardias P et al.

Source: European journal of immunology [Eur J Immunol] 2025 Oct; Vol. 55 (10), pp. e70063.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 1273201 Publication Model: Print Cited Medium: Internet ISSN: 1521-4141 (Electronic) Linking ISSN: 00142980 NLM ISO Abbreviation: Eur J Immunol Subsets: MEDLINE

MeSH Terms: MicroRNAs*/genetics , Azetidines*/therapeutic use , Azetidines*/pharmacology , Arthritis, Rheumatoid*/drug therapy , Arthritis, Rheumatoid*/immunology , Arthritis, Rheumatoid*/genetics , Sulfonamides*/therapeutic use , Sulfonamides*/pharmacology , T-Lymphocytes, Regulatory*/immunology , T-Lymphocytes, Regulatory*/drug effects , Pyrazoles*/therapeutic use , Pyrazoles*/pharmacology, Humans ; Purines/therapeutic use ; Female ; Middle Aged ; Male ; Adult ; Biomarkers ; Aged

Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.

Authors: Li J Xia W Ji H et al.

Source: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2025 Oct 01; Vol. 64 (10), pp. 5262-5268.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE

MeSH Terms: Azetidines*/therapeutic use , Azetidines*/adverse effects , Purines*/therapeutic use , Pyrazoles*/therapeutic use , Pyrazoles*/adverse effects , Sulfonamides*/therapeutic use , Takayasu Arteritis*/drug therapy, Adult ; Female ; Humans ; Male ; Young Adult ; Drug Therapy, Combination ; Glucocorticoids/therapeutic use ; Glucocorticoids/administration & dosage ; Immunosuppressive Agents/therapeutic use ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors/therapeutic use

308 nm Excimer Laser Combined With JAK Inhibitors for Adult Localized Non-Segmental Vitiligo: A Multicenter Randomized Controlled Trial.

Authors: Qi Z Zhang L Chang S et al.

Source: International journal of dermatology [Int J Dermatol] 2025 Dec; Vol. 64 (12), pp. 2283-2291. Date of Electronic Publication: 2025 Jul 19.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Blackwell Science Country of Publication: England NLM ID: 0243704 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-4632 (Electronic) Linking ISSN: 00119059 NLM ISO Abbreviation: Int J Dermatol Subsets: MEDLINE

MeSH Terms: Vitiligo*/therapy , Janus Kinase Inhibitors*/therapeutic use , Janus Kinase Inhibitors*/adverse effects , Lasers, Excimer*/therapeutic use , Lasers, Excimer*/adverse effects , Sulfonamides*/therapeutic use , Azetidines*/therapeutic use , Low-Level Light Therapy*/methods, Humans ; Male ; Female ; Adult ; Middle Aged ; Treatment Outcome ; Combined Modality Therapy/methods ; Young Adult ; Purines/therapeutic use ; Dermoscopy ; Skin Pigmentation/radiation effects ; Skin Pigmentation/drug effects ; Recurrence ; Severity of Illness Index ; Pyrazoles

Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.

Authors: Krishnan V Keller SY Chew C et al.

Source: The Lancet. Rheumatology [Lancet Rheumatol] 2025 Nov; Vol. 7 (11), pp. e799-e807. Date of Electronic Publication: 2025 Sep 04.

Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: MEDLINE

MeSH Terms: Arthritis, Juvenile*/drug therapy , Arthritis, Juvenile*/blood , Azetidines*/therapeutic use , Antirheumatic Agents*/therapeutic use , Sulfonamides*/therapeutic use , Pyrazoles*/therapeutic use, Humans ; Purines/therapeutic use ; Child ; Male ; Adolescent ; Female ; Biomarkers/blood ; Double-Blind Method ; Child, Preschool ; Treatment Outcome

Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells.

Authors: Simiczyjew A Kot M Majkowski M et al.

Source: Cell communication and signaling : CCS [Cell Commun Signal] 2025 Oct 21; Vol. 23 (1), pp. 449. Date of Electronic Publication: 2025 Oct 21.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101170464 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-811X (Electronic) Linking ISSN: 1478811X NLM ISO Abbreviation: Cell Commun Signal Subsets: MEDLINE

MeSH Terms: Vemurafenib*/pharmacology , Melanoma*/pathology , Melanoma*/metabolism , Azetidines*/pharmacology , Drug Resistance, Neoplasm*/drug effects , Piperidines*/pharmacology , Indoles*/pharmacology , Sulfonamides*/pharmacology, Humans ; Cell Line, Tumor ; Cell Movement/drug effects ; Phenotype ; Neoplasm Invasiveness ; Focal Adhesions/metabolism ; Focal Adhesions/drug effects ; Actins/metabolism

The effect of baricitinib on pSTAT3 levels in IL-6- or IL-15-stimulated PBMCs isolated from patients with SLE.

Authors: Szebeni GJ Gémes N Neuperger P et al.

Source: Frontiers in immunology [Front Immunol] 2025 Oct 21; Vol. 16, pp. 1675350. Date of Electronic Publication: 2025 Oct 21 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: STAT3 Transcription Factor*/metabolism , Azetidines*/pharmacology , Purines*/pharmacology , Lupus Erythematosus, Systemic*/immunology , Lupus Erythematosus, Systemic*/drug therapy , Lupus Erythematosus, Systemic*/metabolism , Sulfonamides*/pharmacology , Interleukin-6*/pharmacology , Interleukin-6*/immunology , Pyrazoles*/pharmacology , Leukocytes, Mononuclear*/immunology , Leukocytes, Mononuclear*/drug effects , Leukocytes, Mononuclear*/metabolism , Interleukin-15*/pharmacology , Interleukin-15*/immunology, Humans ; Female ; Adult ; Male ; Middle Aged ; Phosphorylation/drug effects ; Signal Transduction/drug effects